CSI Market
Sign In | Register

Kiora Pharmaceuticals Inc (KPRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KPRX Annual Cash Flow →
Looking at cash flow data from Kiora Pharmaceuticals Inc through Jun 30 2025 provides insight into Jun 30 2026's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-4.50
Depreciation & amortization0.02
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.10
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.32
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Right Of Use Assets0.03
Contingent Consideration-
Change In Fair Value Of Contingent Consideration-
Increase Decrease In Operating Lease Liability-0.04
Increase Decrease In Accrued Interest On Marketable Securities-
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liabilities0.01
Fair Value Adjustment And Investment Income Of Marketable Securities And Cash Equivalents0.06
Change In Unrealized Gain Loss On Cash Equivalents-
Income taxes0.00
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Accounts Receivable-0.29
Increase (Decrease) in Accounts Payable-0.68
Increase (Decrease) in Accrued Liabilities-0.43
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.14
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.01
Payments for (Proceeds from) Other Operating Activities0.23
Discontinued operations0.00
Net Cash flow from Operating Activities-5.05
Investing Activities
Capital Expenditures-0.03
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities7.66
Payments to Acquire Available-for-sale Securities, Debt-9.12
Real Estate Investments0.00
Proceeds From Sale Of Panoptes-
Proceeds From Dissolution Of Foreign Entity-
Conversion Of Stock Amount Converted-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.49
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.93
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.01
Other net0.00
Proceeds From Convertible Notes Payable-
Payment Towards Grants Refund-
Payments For Settlement Of Fractional Shares-
Cash Outflow From Loan Forgiveness-
Payments For Fractional Shares Related To Reverse Stock Split-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.92
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.08
Total Cash Flow-1.62
4 historic quarters locked

Sign in to unlock the full Kiora Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Kiora Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001372514-26-000074

Figures are derived from filed reports and may be restated. Historical data is subject to revision.